Prosight Management LP Increases Position in Immunome, Inc. (NASDAQ:IMNM)

Prosight Management LP increased its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 38.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,342 shares of the company’s stock after buying an additional 15,207 shares during the quarter. Prosight Management LP owned about 0.07% of Immunome worth $577,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in IMNM. Millennium Management LLC acquired a new position in Immunome during the fourth quarter valued at $1,683,000. Granahan Investment Management LLC acquired a new position in Immunome during the fourth quarter valued at $3,337,000. Enavate Sciences GP LLC acquired a new position in Immunome during the fourth quarter valued at $36,939,000. Deutsche Bank AG lifted its position in Immunome by 50.8% during the fourth quarter. Deutsche Bank AG now owns 46,075 shares of the company’s stock valued at $489,000 after purchasing an additional 15,514 shares during the period. Finally, Crestline Management LP acquired a new position in Immunome during the fourth quarter valued at $263,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Immunome

In other Immunome news, Director Jean Jacques Bienaime acquired 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average price of $8.21 per share, with a total value of $57,470.00. Following the purchase, the director now owns 23,615 shares in the company, valued at approximately $193,879.15. The trade was a 42.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Philip Tsai purchased 12,300 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was purchased at an average cost of $8.42 per share, with a total value of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 156,400 shares of company stock valued at $1,160,495. Corporate insiders own 8.60% of the company’s stock.

Immunome Stock Up 0.8%

IMNM stock opened at $7.97 on Thursday. The stock has a market capitalization of $693.49 million, a P/E ratio of -0.98 and a beta of 2.00. The firm has a 50-day simple moving average of $7.68 and a 200-day simple moving average of $9.88. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.81.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $0.46 million. On average, analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $21.00 price objective (down previously from $33.00) on shares of Immunome in a research report on Tuesday. Stephens reiterated an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Guggenheim cut their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 20th. Lake Street Capital started coverage on shares of Immunome in a research note on Wednesday, April 2nd. They set a “buy” rating and a $23.00 target price for the company. Finally, Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has an average rating of “Buy” and an average price target of $23.33.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.